Search

Displaying results 2171 - 2180 of 6949 in total
  1. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    Originally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.[A258298] … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.

  2. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as … [A244564, A244569, A244574, A244584] Etrolizumab is currently under investigation for the treatment of ulcerative colitis and Crohn's disease.

    Categories: Integrin Receptor Antagonist
  3. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

  4. Drug

    Eluxadoline

    go.drugbank.com/drugs/DB09272
    ApprovedInvestigational

    Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). … Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms

    Categories: mu-Opioid Receptor Agonist
  5. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.

    Categories: Corticosteroids for Systemic Use
  7. Drug

    Aminoglutethimide

    go.drugbank.com/drugs/DB00357
    ApprovedWithdrawn

    It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

  8. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354] … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.

  9. Drug

    Tofacitinib

    go.drugbank.com/drugs/DB08895
    ApprovedInvestigational

    Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.

    Categories: Biologics for Rheumatoid Arthritis Treatment
  10. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    At concentrations normally found in the environment however, cresols do not pose any significant risk for the general population.